Prevention of mother-to-child transmission (PMTCT) programs have been largely scaled-up, but data on infant HIV drug resistance from PMTCT programs implemented in resource-limited countries are lacking.
Remnant dried blood spots (DBS) from HIV-infected children (aged <18 months) tested through the Togo national early infant diagnosis (EID) program during 2012 and 2013, were collected and assessed for HIV drug resistance. Pol-RT (reverse transcriptase) region was amplified, sequenced and analyzed for presence of drug resistance mutations (DRMs).
Overall,121/201 (60.2%) newly diagnosed children had detectable DRMs.. Among the 131/201 (65.2%) children with reported exposure to maternal and/or infant ARVs, 99/131 (75.6%) had DRMs detected. Importantly, of 41/201 children for whom no exposure to ARVs was reported, DRMs were detected in 11 (26.8%). For 29 children no data on ARV exposure were available. For the 121/201 children with DRMs, 99/121 (81.8%) had only non-nucleoside reverse transcriptase inhibitors (NNRTIs) DRMs detected but 21/121 (17.3%) had both NNRTI and nucleoside reverse transcriptase inhibitor (NRTI) DRMs. Among breastfed children, drug resistance was more frequent when mothers were on antiretroviral therapy (ART): 61/75 (81.3%) versus 14/39 (35.9%) when mothers were not on ART (p<0.001). NRTI resistance was more common when mothers were on ART.
Scale-up and improvement of PMTCT strategies resulted in a global decrease of pediatric HIV infections, but our study shows high rates of drug resistance in infants for whom prevention failed.